Search

Menashe Bar-Eli

from Houston, TX
Get Report
Related to:
Avivit Bar, 50Yotam B Bareli, 48Avivit BareliEstelle BareliLee H Bareli, 43Menashe Bareli, 76Esther Bareli, 77
Connected to:
Brenda Bara, 47Christina M Bara, 35Ellen S Bara, 76Juan C Bara, 37Michal F Bara, 85Nicolae O Bara, 41Patrick L Bara, 36Rachel A Bara, 56Roberto Bara, 50Sandy L Bara, 57

Menashe Bar-Eli Phones & Addresses

  • 8819 Manhattan Dr, Houston, TX 77096

Work

Company: M.d. anderson cancer center Position: Professor

Education

School / High School: UCLA

Skills

Cancer • Cell Biology • Cancer Research • Molecular Biology • Genetics • Biochemistry • Animal Models • Science • Cell Culture • Biotechnology • Clinical Research • Lifesciences • Drug Discovery

Industries

Hospital & Health Care

Resumes

Resumes

Menashe Bar-Eli Photo 1

Professor

View page
Location:
Houston, TX
Industry:
Hospital & Health Care
Work:
M.D. Anderson Cancer Center
Professor
Education:
UCLA
Skills:
Cancer
Cell Biology
Cancer Research
Molecular Biology
Genetics
Biochemistry
Animal Models
Science
Cell Culture
Biotechnology
Clinical Research
Lifesciences
Drug Discovery

Business Records

Name / Title
Company / Classification
Phones & Addresses
Menashe Bar-Eli
Owner
Bar-Eli, Menashe
Professional Organization
8819 Manhattan Dr, Houston, TX 77096

Publications

Us Patents

Methods For Using Anti-Muc18 Antibodies

View page
US Patent:
7067131, Jun 27, 2006
Filed:
Dec 26, 2002
Appl. No.:
10/330530
Inventors:
Jean Gudas - Los Angeles CA, US
Larry L. Green - San Francisco CA, US
Menashe Bar-Eli - Houston TX, US
Assignee:
Abgenix, Inc. - Fremont CA
International Classification:
A61K 39/395
C07K 16/00
C12P 21/00
C12P 21/04
C12P 21/08
US Classification:
4241421, 4241301, 4241551, 4241561, 4241811, 5303871, 53038815, 53038885, 5303917, 435 696, 800 6
Abstract:
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.

Use Of Antibodies Against The Muc18 Antigen

View page
US Patent:
7090844, Aug 15, 2006
Filed:
Sep 10, 2003
Appl. No.:
10/660357
Inventors:
Menashe Bar-Eli - Houston TX, US
Larry L. Green - San Francisco CA, US
Assignee:
Abgenix, Inc. - Fremont CA
International Classification:
A61K 39/395
C07K 16/00
C12P 21/00
C12P 21/04
C12P 21/08
US Classification:
4241421, 4241301, 4241551, 4241561, 4241811, 5303871, 53038815, 53038885, 5303917, 435 696, 800 6
Abstract:
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.

Therapeutic Targeting Of Interleukins Using Sirna In Neutral Liposomes

View page
US Patent:
8067390, Nov 29, 2011
Filed:
Feb 29, 2008
Appl. No.:
12/527684
Inventors:
William M. Merritt - Houston TX, US
Anil K. Sood - Pearland TX, US
Menashe Bar-Eli - Houston TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
A01N 43/04
A61K 31/70
US Classification:
514 44A
Abstract:
The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides compositions that include an siRNA targeted to an interleukin and a neutral lipid, and methods of treating a human subject with cancer involving administering to the subject a pharmaceutically effective amount of an interleukin-8 antagonist or a composition as set forth herein.

Methods For Inhibition Of Angiogenesis, Tumor Growth And Metastasis By Fully Human Anti-Il8 And Anti-Muc18 In Diverse Types Of Tumors

View page
US Patent:
20030068319, Apr 10, 2003
Filed:
Mar 22, 2002
Appl. No.:
10/104090
Inventors:
Menashe Bar-Eli - Houston TX, US
International Classification:
A61K039/395
US Classification:
424/141100, 424/145100
Abstract:
The present invention relates to methods of inhibiting hyperproliferative diseases. More specifically, it concerns treating a subject suffering from a hyperproliferative disease by administering an effective amount of a human anti-IL8 antibody composition and/or a human anti-MUC18 antibody composition such that the composition inhibits the disease.

Use Of Antibodies Against The Muc18 Antigen

View page
US Patent:
20060246077, Nov 2, 2006
Filed:
Jun 30, 2006
Appl. No.:
11/479339
Inventors:
Menashe Bar-Eli - Houston TX, US
Larry Green - San Francisco CA, US
International Classification:
A61K 39/395
C07H 21/04
C12P 21/06
C07K 16/30
C12N 5/06
US Classification:
424155100, 435069100, 435338000, 435320100, 530388800, 536023530
Abstract:
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.

Antibodies Against The Muc18 Antigen

View page
US Patent:
6924360, Aug 2, 2005
Filed:
Dec 26, 2002
Appl. No.:
10/330613
Inventors:
Larry L. Green - San Francisco CA, US
Menashe Bar-Eli - Houston TX, US
Assignee:
Abgenix, Inc. - Freemont CA
International Classification:
C07K016/00
A61K039/395
US Classification:
5303881, 53038885, 5303913, 5303917, 4241411, 4241561, 4241811, 4241831
Abstract:
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.
Control profile
Menashe Bar-Eli from Houston, TX Get Report